Previous 10 | Next 10 |
Shares of Deciphera Pharmaceuticals (DCPH) have risen by just 1% since my September 2018 article suggested initiating a pilot position in the near term and accumulating weakness. To be fair, I had thought ESMO data for DCC-2618 would boost shares and instead they lost nearly half their value...
Geron (NASDAQ: GERN ) initiated with Overweight rating and $4 (210% upside) price target at Cantor Fitzgerald. Shares up 2% premarket. More news on: Geron Corporation, Blueprint Medicines Corporation, Elanco Animal Health Incorporated, Healthcare stocks news, Stocks on the move...
The FDA accepts for review Blueprint Medicines' ( BPMC +1.2% ) marketing application seeking approval to use avapritinib to treat adult patients with PDGFRA Exon 18-mutant gastrointestinal stromal tumors (GIST), regardless of prior therapy, and fourth-line GIST. The agency's action date ...
CAMBRIDGE, Mass. , Aug. 7, 2019 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that the U.S. Food and Drug Administration (FDA) has accepted the com...
CAMBRIDGE, Mass. , Aug. 6, 2019 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that Andy Boral , M.D., Ph.D., Blueprint Medicines' ...
Blueprint Medicines Corp (BPMC) Q2 2019 Earnings Conference Call August 01, 2019, 08:30 ET Company Participants Kristin Hodous - Senior Manager, IR Jeffrey Albers - CEO, President & Director Christina Rossi - Chief Commercial Officer Michael Landsittel - CFO Anthony Boral...
Blueprint Medicines (NASDAQ: BPMC ): Q2 GAAP EPS of -$2.04 misses by $0.09 . More news on: Blueprint Medicines Corporation, Earnings news and commentary, Healthcare stocks news, Read more ...
CAMBRIDGE, Mass. , Aug. 1, 2019 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today reported financial results and provided a business update for the quarter ...
AAON , AAWW , ABC , ABMD , ADM , AGIO , AKRX , ALE , AMCR , ARW , ASIX , AVP , BCE , BCPC , BLD , BLL , BPL , BPMC , BR , BSIG , CBRE , CI , CLVS , CLX , CNHI , CNQ , CNSL , CROX , CRS , CWT , DD , DEA , DLPH , DNKN , EIGI , EXC , GIL , GLOG , GM , GN...
Idea Slides Introduction RET mutations are seen in ~2% of NSCLCs. Currently, there are no FDA-approved treatments for RET-mutated NSCLC. Multi-targeted drugs have been tested in these patients, but without much success. RET-targeted therapies like Blueprint Medicines' ( BPMC ) and L...
News, Short Squeeze, Breakout and More Instantly...
Blueprint Medicines Corporation Company Name:
BPMC Stock Symbol:
NASDAQ Market:
Blueprint Medicines Corporation Website:
Blueprint Medicines to Report Second Quarter 2024 Financial Results on Thursday, August 1, 2024 PR Newswire CAMBRIDGE, Mass. , July 18, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call an...
2024-07-10 04:20:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
A look at the top 10 most actives in the United States Maxeon Solar Technologies Ltd. (MAXN) rose 12.5% to $0.27 on volume of 477,193,667 shares NVIDIA Corporation (NVDA) rose 1.9% to $128.2 on volume of 232,119,115 shares Virpax Pharmaceuticals Inc. (VRPX) rose 92.0% to $1.11 on volume o...